secwatch / observer
8-K filed June 4, 2026, 4:30 PM ET ticker MDCX CIK 0001997296
other material confidence high sentiment neutral materiality 0.55

Medicus Pharma shareholders approve up to 50:1 reverse stock split at special meeting

Medicus Pharma Ltd.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Medicus Pharma Ltd. shareholders approved Shareholders approved the special resolution authorizing the Board, in its discretion, to effect a consolidation of the Company's common shares, no par value (the "Common Shares") on the basis of a consolidation ratio to be determined by the Board, up to a maximum ratio of 50 pre-consolidation Commo at the 2026-06-03 meeting.

Proposal
reverse split
Outcome
passed
Meeting
2026-06-03
Exact text from the filing
Shareholders approved the special resolution authorizing the Board, in its discretion, to effect a consolidation of the Company's common shares, no par value (the "Common Shares") on the basis of a consolidation ratio to be determined by the Board, up to a maximum ratio of 50 pre-consolidation Common Shares for every one post-consolidation Common Share, if the Board determines such a consolidation is necessary or desirable, including, without limitation, for the purpose of meeting any applicable stock exchange or regulatory requirements. Shareholder approval of this Proposal 3 required the affirmative vote of at least two-thirds of the votes cast by the shareholders present at the Meeting in person or by proxy: For Against Abstain Broker Non-Votes 26,729,776 2,335,461 N/A 1
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Medicus Pharma Ltd. shareholders approved Shareholders elected all nine of the directors nominated by the Board to serve for one-year terms, until our 2027 annual meeting of shareholders or until their successors are duly elected or appointed, unless they resign, are removed, or become disqualified in accordance with the Articles of Incorpo at the 2026-06-03 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-03
Exact text from the filing
Shareholders elected all nine of the directors nominated by the Board to serve for one-year terms, until our 2027 annual meeting of shareholders or until their successors are duly elected or appointed, unless they resign, are removed, or become disqualified in accordance with the Articles of Incorporation of the Company (the "Articles") or the Business Corporations Act (Ontario): Name For Withhold Abstain Broker Non-Votes William L. Ashton 15,181,189 354,284 N/A 13,529,765 Dr. Raza Bokhari 15,068,465 467,008 N/A 13,529,765 Robert J. Ciaruffoli 15,186,431 349,042 N/A 13,529,765 Barry Fishman 15,189,646 345,827 N/A 13,529,765 Dr. Larry Kaiser 15,198,014 337,459 N/A 13,529,765 Patrick Mahaffy 15,193,804 341,669 N/A 13,529,765 Dr. Sara R. May 15,192,642 342,831 N/A 13,529,765 Hon. Cathy McMorris Rodgers 15,178,833 356,640 N/A 13,529,765 Ajay Raju 15,190,298 345,175 N/A 13,529,765
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Medicus Pharma Ltd. shareholders approved Shareholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the Company's 2026 fiscal year and the authorization of the Company's board of directors to fix the auditors' remuneration and terms of engagement at the 2026-06-03 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-03
Exact text from the filing
Shareholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the Company's 2026 fiscal year and the authorization of the Company's board of directors (the "Board") to fix the auditors' remuneration and terms of engagement: For Withhold Abstain Broker Non-Votes 28,308,860 756,378 N/A 0
View on SEC.gov

1593 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Medicus Pharma Ltd. filing history →

Source: SEC EDGAR
accession 0001062993-26-003060
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.